Leavell Investment Management Inc. Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)

Leavell Investment Management Inc. bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,000 shares of the company's stock, valued at approximately $340,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. Wood Tarver Financial Group LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $30,000. Ameriflex Group Inc. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $36,000. NBC Securities Inc. grew its position in shares of CRISPR Therapeutics by 156,300.0% in the first quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock valued at $53,000 after purchasing an additional 1,563 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $71,000. Finally, Elkhorn Partners Limited Partnership grew its position in shares of CRISPR Therapeutics by 22.6% in the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,800 shares of the company's stock valued at $150,000 after purchasing an additional 700 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CRSP shares. Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Piper Sandler restated an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. HC Wainwright restated a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. JMP Securities restated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Finally, Chardan Capital restated a "buy" rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, June 26th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Stock Up 4.6%

Shares of CRSP stock traded up $2.41 during mid-day trading on Wednesday, reaching $55.14. The company's stock had a trading volume of 3,312,961 shares, compared to its average volume of 1,963,386. The company's 50 day simple moving average is $43.29 and its 200-day simple moving average is $41.48. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $63.68. The firm has a market capitalization of $4.76 billion, a PE ratio of -12.20 and a beta of 1.82.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same quarter in the previous year, the company posted ($1.43) EPS. The company's revenue was up 71.6% compared to the same quarter last year. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the transaction, the insider directly owned 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.